CMB (CMB) News
Follow CMB (CMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Cambium Bio raises A$10.85m for Phase 3 dry eye trial
Strategic shareholders committed A$7.1m at a premium to market, and the company secured A$3.75m via non-dilutive R&D Tax Incentive pre-financing, funding Phase 3 of Elate Ocular® for dry eye disease.
EQUITY | Sep 16, 2026, 04:42 AM UTC
L
Cambium Bio announces change in company secretary
Cambium Bio announced a change in company secretary.
EQUITY | Aug 27, 2026, 01:38 AM UTC